{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.10","value":"3.00"},{"groupId":"OG001","spread":"0.71","value":"2.50"},{"groupId":"OG002","spread":"1.88","value":"3.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Side efect burden was defined as the total score of the UKU Side Effects Rating Scale. This scale contains 48 items corresponding to side effects which are rated from 0-3, with 0 meaning not present and 1-3 rating the severity of the side effect. Higher scores represented greater side effect burden. The scale range is 0 to 144.","dispersionType":"Standard Deviation","groups":[{"description":"Participants in this arm were randomized to receive placebo for the first 4 weeks and placebo for the second 4 weeks","id":"OG000","title":"Placebo-Placebo"},{"description":"Participants in this arm were randomized to receive placebo for the first 4 weeks and escitalopram for the second 4 weeks","id":"OG001","title":"Placebo-Escitalopram"},{"description":"Participants in this arm were randomzied to receive escitalopram for the first 4 weeks and placebo for the second 4 weeks","id":"OG002","title":"Escitalopram-Placebo"}],"paramType":"MEAN","populationDescription":"Participants who completed the 4 week assessment were analyzed","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Side Effect Burden","type":"SECONDARY","unitOfMeasure":"units on a scale"}